Hepion Pharmaceuticals, Inc.

NasdaqCM:HEPA Rapport sur les actions

Capitalisation boursière : US$3.8m

Hepion Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

We currently do not have sufficient information about the CEO.

Informations clés

John Brancaccio

Directeur général

US$81.0k

Rémunération totale

Pourcentage du salaire du PDGn/a
Durée du mandat du directeur généralless than a year
Propriété du PDG0.006%
Durée moyenne d'occupation des postes de directionpas de données
Durée moyenne du mandat des membres du conseil d'administration2yrs

Mises à jour récentes de la gestion

Recent updates

Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

Aug 10
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Apr 25
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Oct 27
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharma rises as company begins NASH treatment trial

Aug 31

Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Jul 04
Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH

Feb 17

Hepion Pharmaceuticals: Facing The Momentous Year 2022

Jan 21

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Sep 21

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Sep 14
Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Sep 08

Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)

May 26

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Feb 18
What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Hepion Pharma cleared to advance final dosing cohort in NASH trial

Dec 29

Hepion Pharma to begin CRV431 testing in COVID-19 patients

Dec 22

Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study

Dec 10

Hepion Pharma prices equity offering at $1.50

Nov 25

Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow

Oct 31

PDG

John Brancaccio (76 yo)

less than a year

Titularisation

US$81,000

Compensation

Mr. John Patrick Brancaccio, C.P.A, serves as Independent Non-Executive Director at Tiziana Life Sciences plc since July 2020. He is an Independent Non-Executive Director at OKYO Pharma Limited since June...

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
John Brancaccio
Interim CEO11.5yrsUS$81.00k0.0060%
$ 228.1
Timothy M. Block
Independent Director11yrsUS$72.90k0.0060%
$ 228.1
Vlad Ratziu
Member of Scientific Advisory Board1.7yrspas de donnéespas de données
Rohit Loomba
Member of Scientific Advisory Board1.7yrspas de donnéespas de données
Stephen A. Harrison
Scientific Advisory Board Chair5.3yrspas de donnéespas de données
Nikolai Naoumov
Member of Scientific Advisory Board1.7yrspas de donnéespas de données
Philippe Gallay
Member of Scientific Advisory Board8.3yrspas de donnéespas de données
Michael Purcell
Independent Directorless than a yearpas de donnéespas de données
Yury Popov
Member of Scientific Advisory Board1.7yrspas de donnéespas de données
Kaouthar Lbiati
Independent Director2.4yrsUS$80.50kpas de données

2.0yrs

Durée moyenne de l'emploi

68yo

Âge moyen

Conseil d'administration expérimenté: HEPA's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.